Bortezomib sensitizes malignant human glioma cells to TRAIL, mediated by inhibition of the NF-{kappa}B signaling pathway.
about
Trailing TRAIL Resistance: Novel Targets for TRAIL Sensitization in Cancer CellsHigh-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells.PID1 increases chemotherapy-induced apoptosis in medulloblastoma and glioblastoma cells in a manner that involves NFκB.Inhibition of phosphatidylinositol 3-kinase/AKT signaling by NVP-BKM120 promotes ABT-737-induced toxicity in a caspase-dependent manner through mitochondrial dysfunction and DNA damage response in established and primary cultured glioblastoma cells.Bortezomib-induced sensitization of malignant human glioma cells to vorinostat-induced apoptosis depends on reactive oxygen species production, mitochondrial dysfunction, Noxa upregulation, Mcl-1 cleavage, and DNA damage.The TRAIL of oncogenes to apoptosis.A curated census of autophagy-modulating proteins and small molecules: candidate targets for cancer therapy.NVP-BKM120 potentiates apoptosis in tumor necrosis factor-related apoptosis-inducing ligand-resistant glioma cell lines via upregulation of Noxa and death receptor 5.ABT-737 synergizes with bortezomib to induce apoptosis, mediated by Bid cleavage, Bax activation, and mitochondrial dysfunction in an Akt-dependent context in malignant human glioma cell lines.Cucurbitacin-I inhibits Aurora kinase A, Aurora kinase B and survivin, induces defects in cell cycle progression and promotes ABT-737-induced cell death in a caspase-independent manner in malignant human glioma cellsInhibition of NF-κB Pathway and Modulation of MAPK Signaling Pathways in Glioblastoma and Implications for Lovastatin and Tumor Necrosis Factor-Related Apoptosis Inducing Ligand (TRAIL) Combination Therapy.The inhibitory effect of MSCs expressing TRAIL as a cellular delivery vehicle in combination with cisplatin on hepatocellular carcinoma.Kurarinone promotes TRAIL-induced apoptosis by inhibiting NF-κB-dependent cFLIP expression in HeLa cells.YM-155 potentiates the effect of ABT-737 in malignant human glioma cells via survivin and Mcl-1 downregulation in an EGFR-dependent context.Intracranial AAV-sTRAIL combined with lanatoside C prolongs survival in an orthotopic xenograft mouse model of invasive glioblastoma.Effect of Corilagin on the Proliferation and NF-κB in U251 Glioblastoma Cells and U251 Glioblastoma Stem-Like Cells.Survivin inhibitor YM-155 sensitizes tumor necrosis factor- related apoptosis-inducing ligand-resistant glioma cells to apoptosis through Mcl-1 downregulation and by engaging the mitochondrial death pathwaySystemically administered AAV9-sTRAIL combats invasive glioblastoma in a patient-derived orthotopic xenograft model.Proteasomal regulation of caspase-8 in cancer cell apoptosisModulation of Mcl-1 sensitizes glioblastoma to TRAIL-induced apoptosisAutophagy and oxidative stress in gliomas with IDH1 mutationsTRAIL combinations: The new 'trail' for cancer therapy (Review).Potential usage of proteasome inhibitor bortezomib (Velcade, PS-341) in the treatment of metastatic melanoma: basic and clinical aspectsNovel siRNA delivery strategy: a new "strand" in CNS translational medicine?Mechanisms of proteasome inhibitor-induced cytotoxicity in malignant glioma.Axitinib induces senescence-associated cell death and necrosis in glioma cell lines: The proteasome inhibitor, bortezomib, potentiates axitinib-induced cytotoxicity in a p21(Waf/Cip1) dependent manner.Bortezomib sensitizes human glioblastoma cells to induction of apoptosis by type I interferons through NOXA expression and Mcl-1 cleavageCombination Treatment with Sublethal Ionizing Radiation and the Proteasome Inhibitor, Bortezomib, Enhances Death-Receptor Mediated Apoptosis and Anti-Tumor Immune Attack.Dual Agonist Surrobody Simultaneously Activates Death Receptors DR4 and DR5 to Induce Cancer Cell Death.Icaritin Sensitizes Human Glioblastoma Cells to TRAIL-Induced Apoptosis.Combination treatment for glioblastoma cells with tumor necrosis factor-related apoptosis-inducing ligand and oncolytic adenovirus delta-24.The DeISGylase USP18 limits TRAIL-induced apoptosis through the regulation of TRAIL levels: Cellular levels of TRAIL influences responsiveness to TRAIL-induced apoptosis.Inhibition of autophagy enhances apoptosis induced by proteasome inhibitor bortezomib in human glioblastoma U87 and U251 cells.Combined inhibition of DNA methyltransferase and histone deacetylase restores caspase-8 expression and sensitizes SCLC cells to TRAIL.Proteasome Stress Triggers Death of SH-SY5Y and T98G Cells via Different Cellular Mechanisms.Amentoflavone Induces Apoptosis and Inhibits NF-ĸB-modulated Anti-apoptotic Signaling in Glioblastoma Cells.Different effects of bortezomib on the expressions of various protein kinase C isoenzymes in T cells of patients with systemic lupus erythematosus and in Jurkat cells.Microenvironmental agonists generate phenotypic resistance to combined ibrutinib plus venetoclax in CLL and MCL
P2860
Q28391040-D15D9951-25FB-4F3B-86AC-FE60315A0454Q30433183-828E42E1-E14E-451E-861F-7078C3D38F06Q33678251-7EAEB9A1-1B35-4F0A-A2EA-13E0FA6F4138Q33750838-EECFC452-71ED-4745-A448-246214600671Q33798624-1382FC4C-A820-4DAA-BB16-8168CE929CB1Q34354511-7A440C0A-1770-4CF9-A221-F48F6D56045FQ34373138-75CBE329-5931-4344-A44B-25EE0EE6D5C7Q35849961-F3860B36-8D7F-4E15-BE7F-E39DA26F6114Q35996719-DFE8838E-BED5-498D-B687-306AF8B563D8Q36214610-907DB0E0-E27B-40CA-B744-14C8430C3E33Q36263997-FCF9AA11-9688-4DE5-BBBA-B46CC7392ACFQ36312145-2E22A3F7-1AA8-4B2B-BA1D-13C0AE728C1BQ36431068-DC094E54-6E83-4CF5-87D1-83DD2C877A5FQ36681060-107BDA11-D84A-46D3-B468-F2FF289E7158Q36784375-461705F9-B903-48D0-B782-62A9B2016DADQ36924817-79107DD2-D282-4DD0-914F-792338500D87Q37027010-B376EE83-B03C-4DF4-A0CF-513F294961ACQ37028654-CB74283F-7669-4523-93CB-3A1A6BB71C87Q37146270-95D1D713-F79C-49DB-B843-10ADAB5B232AQ37610475-1233D964-486C-46C6-9133-152D3D016B81Q37625457-56CD4740-2333-443F-84A7-E955B08A6307Q37719944-BF2DFE37-E032-4FBA-845E-0A747BBF7687Q37948056-18DECFF1-0CA7-4A36-BB70-B380247E6FF0Q38091009-6C332873-99D3-406F-A156-CFC8FC440A0DQ38111684-5DB9DA5A-3A0E-4173-81A7-48A78DBEDF48Q38727281-02514A9B-736B-41A3-84C1-987C3CBED071Q38756202-BDF93C68-B94C-4772-8019-C4EFD77D2304Q38809124-E93632FD-0004-40C4-9C3C-6C630A1039C5Q38823727-25B3F823-1070-4C99-A91E-63563ED6D597Q38921239-7DEAB5D3-1867-4E0F-B541-F3492C1B821AQ39069742-490D86F7-AA64-4AFC-8EDC-50F2FE8C5F9DQ39072507-5EC7A662-27D3-4027-80BC-DEEDEDE6CBB0Q39084493-905311D3-868E-4F50-867D-6EE64B572280Q42730361-ED5084E3-3C42-43E5-993A-F5326BED584CQ50880972-73FCB714-A704-483F-ABEC-BB35B0486923Q52730709-944E61F5-CD26-45C0-885F-35BA30E98C43Q53975226-67F52344-035F-4925-9F97-E01D6C784CA3Q56514276-4A3D466D-4945-4492-8441-2FD1D73C0D9E
P2860
Bortezomib sensitizes malignant human glioma cells to TRAIL, mediated by inhibition of the NF-{kappa}B signaling pathway.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Bortezomib sensitizes malignan ...... NF-{kappa}B signaling pathway.
@ast
Bortezomib sensitizes malignan ...... NF-{kappa}B signaling pathway.
@en
Bortezomib sensitizes malignan ...... NF-{kappa}B signaling pathway.
@nl
type
label
Bortezomib sensitizes malignan ...... NF-{kappa}B signaling pathway.
@ast
Bortezomib sensitizes malignan ...... NF-{kappa}B signaling pathway.
@en
Bortezomib sensitizes malignan ...... NF-{kappa}B signaling pathway.
@nl
prefLabel
Bortezomib sensitizes malignan ...... NF-{kappa}B signaling pathway.
@ast
Bortezomib sensitizes malignan ...... NF-{kappa}B signaling pathway.
@en
Bortezomib sensitizes malignan ...... NF-{kappa}B signaling pathway.
@nl
P2093
P2860
P1476
Bortezomib sensitizes malignan ...... NF-{kappa}B signaling pathway.
@en
P2093
Daniel R Premkumar
Esther P Jane
Ian F Pollack
P2860
P304
P356
10.1158/1535-7163.MCT-10-0725
P577
2011-01-01T00:00:00Z